Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade

Checkpoint blockade with Pembrolizumab, has demonstrated durable clinical responses in advanced non-small cell lung cancer, however, treatment is offset by the development of high-grade immune related adverse events (irAEs) in some patients. Here, we show that in these patients a deficient Breg chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Akshay J., Willsmore, Zena N., Khan, Naeem, Richter, Alex, Naidu, Babu, Drayson, Mark T., Papa, Sophie, Cope, Andrew, Karagiannis, Sophia N., Perucha, Esperanza, Middleton, Gary W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174492/
https://www.ncbi.nlm.nih.gov/pubmed/35672305
http://dx.doi.org/10.1038/s41467-022-30863-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174492/
https://www.ncbi.nlm.nih.gov/pubmed/35672305
http://dx.doi.org/10.1038/s41467-022-30863-x

Ejemplares similares